Topical therapies for the treatment of plaque psoriasis: Systematic review and network meta-analyses

British Journal of Dermatology

Volumn 168, Issue 5, 2013, Pages 954-967

  Samarasekera, E J ^a   Sawyer, L ^b   Wonderling, D ^a   Tucker, R ^c   Smith, C H ^d  

^a ROYAL COLLEGE OF PHYSICIANS   (United Kingdom)

^b Showa University Koto Hospital   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; COAL TAR; CORTICOSTEROID; DITHRANOL; PLACEBO; RETINOID; VITAMIN D;

COMPARATIVE STUDY; CORTICOSTEROID THERAPY; DATA EXTRACTION; DISEASE SEVERITY; HUMAN; LIMB; META ANALYSIS; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSORIASIS VULGARIS; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCALP; SYSTEMATIC REVIEW; TREATMENT DURATION; TRUNK;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; COAL TAR; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; EXTREMITIES; HUMANS; KERATOLYTIC AGENTS; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETINOIDS; SCALP; TIME FACTORS; TORSO; TREATMENT OUTCOME; VITAMIN D;

EID: 84876978987     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12276     Document Type: Review

References (78)

1. Rapp SR, Feldman SR, Exum ML, et al,. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
2. Kurd SK, Gelfand JM,. The prevalence of previously diagnosed and undiagnosed psoriasis in U.S. adults: results from NHANES 2003-2004. J Am Acad Dermatol 2009; 60: 218-24.
3. Schmitt JM, Ford DE,. Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology 2006; 213: 102-10.
4. Dubertret L, Mrowietz U, Ranki A, et al,. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-36.
5. Smith CH, Barker JN,. Psoriasis and its management. BMJ 2006; 333: 380-4.
6. Bewley A, Page B,. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol 2011; 25 (Suppl. 4): 9-14.
7. Sawyer L, Samarasekera EJ, Wonderling D, Smith CH,. Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis. Br J Dermatol 2013; 168: 1095-105.
8. National Clinical Guideline Centre. Psoriasis: Assessment and Management of Psoriasis. London: National Clinical Guideline Centre, 2012.
9. Caldwell DM, Ades AE, Higgins JP,. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331: 897-900.
10. Bucher HC, Guyatt GH, Griffith LE, Walter SD,. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol 1997; 50: 683-91.
11. Barker JN, Griffiths CE,. Combination therapy for psoriasis. Dermatol Ther 1999; 11: 96-103.
12. Perez A, Chen TC, Turner A, et al,. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134: 238-46.
13. Fleming C, Ganslandt C, Guenther L, et al,. Calcipotriol plus betamethasone dipropionate gel compared with its active components in the same vehicle and the vehicle alone in the treatment of psoriasis vulgaris: a randomised, parallel group, double-blind, exploratory study. Eur J Dermatol 2010; 20: 465-71.
14. Kaufmann R, Bibby A, Bissonnette R, et al,. A new calcipotriol/ betamethasone dipropionate formulation (Daivobet™) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-93.
15. Langley RG, Gupta A, Papp K, et al,. Calcipotriol plus betamethasone dipropionate gel compared with tacalcitol ointment and the gel vehicle alone in patients with psoriasis vulgaris: a randomized, controlled clinical trial. Dermatology 2011; 222: 148-56.
16. Medansky RS, Brody NI, Kanof NB, et al,. Clinical investigations of mometasone furoate-a novel nonfluorinated, topical corticosteroid. Semin Dermatol 1987; 6: 94-100.
17. Decroix J, Pres H, Tsankov N, et al,. Clobetasol propionate lotion in the treatment of moderate to severe plaque-type psoriasis. Cutis 2004; 74: 201-6.
18. Weinstein GD, Koo JY, Krueger GG, et al,. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0·05% and 0·1% applied once daily for 12 weeks. J Am Acad Dermatol 2003; 48: 760-7.
19. 3 (calcitriol) ointment in psoriasis. J Dermatolog Treat 1992; 3: 177-80.
20. Langner A, Verjans H, Stapõr V, et al,. Topical calcitriol in the treatment of chronic plaque psoriasis: a double-blind study. Br J Dermatol 1993; 128: 566-71.
21. Highton A, Quell J,. Calcipotriene ointment 0·005% for psoriasis: a safety and efficacy study. Calcipotriene Study Group. J Am Acad Dermatol 1995; 32: 67-72.
22. Dubertret L, Wallach D, Souteyrand P, et al,. Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle-controlled study. J Am Acad Dermatol 1992; 27: 983-8.
23. Harrington CI, Goldin D, Lovell CR, et al,. Comparative effects of two different calcipotriol (MC 903) cream formulations versus placebo in psoriasis vulgaris. A randomised, double-blind, placebo-controlled, parallel group multi-centre study. J Eur Acad Dermatol Venereol 1996; 6: 152-8.
24. Papp KA, Guenther L, Boyden B, et al,. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003; 48: 48-54.
25. Guenther L, van de Kerkhof PC, Snellman E, et al,. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002; 147: 316-23.
26. Wortzel WH,. A new corticosteroid for moderate/severe dermatoses. Clin Med 1975; 82: 23-6.
27. Sears HW,. A double-blind, randomized, placebo-controlled evaluation of the efficacy and safety of hydrocortisone buteprate 0·1% cream in the treatment of psoriasis. Adv Ther 1997; 14: 140-9.
28. Lowe N, Feldman SR, Sherer D, et al,. Clobetasol propionate lotion, an efficient and safe alternative to clobetasol propionate emollient cream in subjects with moderate to severe plaque-type psoriasis. J Dermatolog Treat 2005; 16: 158-64.
29. Gottlieb A, Chaudhari U, Baker D, et al,. The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. J Drugs Dermatol 2003; 2: 260-6.
30. Lebwohl M, Sherer D, Washenik K, et al,. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0·05% foam in the treatment of nonscalp psoriasis. Int J Dermatol 2002; 41: 269-74.
31. Jarratt MT, Clark SD, Savin RC, et al,. Evaluation of the efficacy and safety of clobetasol propionate spray in the treatment of plaque-type psoriasis. Cutis 2006; 78: 348-54.
32. Kragballe K, Barnes L, Hamberg KJ, et al,. Calcipotriol cream with or without concurrent topical corticosteroid in psoriasis: tolerability and efficacy. Br J Dermatol 1998; 139: 649-54.
33. Ortonne P, Kaufmann R, Lecha M, Goodfield M,. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcitol for the treatment of psoriasis vulgaris: a randomised, double-blind trial. Dermatology 2004; 209: 308-13.
34. Camarasa JM, Ortonne JP, Dubertret L,. Calcitriol shows greater persistence of treatment effect than betamethasone dipropionate in topical psoriasis therapy. J Dermatolog Treat 2003; 14: 8-13.
35. Molin L,. Does addition of topical calcipotriol to UVB increase the risk of irritant reactions in psoriasis? The Calcipotriol-UVB study group Acta Derm Venereol 1997; 77: 401-2.
36. Kragballe K, Gjertsen BT, de Hoop D, et al,. Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet 1991; 337: 193-6.
37. Cunliffe WJ, Berth-Jones J, Claudy A, et al,. Comparative study of calcipotriol (MC 903) ointment and betamethasone 17-valerate ointment in patients with psoriasis vulgaris. J Am Acad Dermatol 1992; 26: 736-43.
38. Douglas WS, Poulin Y, Decroix J, et al,. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002; 82: 131-5.
39. Ruzicka T, Lorenz B,. Comparison of calcipotriol monotherapy and a combination of calcipotriol and betamethasone valerate after 2 weeks' treatment with calcipotriol in the topical therapy of psoriasis vulgaris: a multicentre, double-blind, randomized study. Br J Dermatol 1998; 138: 254-8.
40. Tham SN, Lun KC, Cheong WK,. A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis. Br J Dermatol 1994; 131: 673-7.
41. Alora-Palli MB, Perkins AC, Van Cott A, Kimball AB,. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream. Am J Clin Dermatol 2010; 11: 275-83.
42. Pinheiro N,. Comparative effects of calcipotriol ointment (50 μg/g) and 5% coal tar/2% allantoin/0·5% hydrocortisone cream in treating plaque psoriasis. Br J Clin Pract 1997; 51: 16-19.
43. Hutchinson P, Marks R, White J,. The efficacy, safety and tolerance of calcitriol 3 μg/g ointment in the treatment of plaque psoriasis: a comparison with short-contact dithranol. Dermatology 2000; 201: 139-45.
44. Wall AR, Poyner TF, Menday AP,. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. Br J Dermatol 1998; 139: 1005-11.
45. Berth-Jones J, Chu AC, Dodd WA, et al,. A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis. Br J Dermatol 1992; 127: 266-71.
46. Christensen OB, Mork N-J, Ashton R, et al,. Comparison of a treatment phase and a follow-up phase of short-contact dithranol and calcipotriol in outpatients with chronic plaque psoriasis. J Dermatolog Treat 1999; 10: 261-5.
47. Oranje AP, Marcoux D, Svensson A, et al,. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol 1997; 36: 203-8.
48. Menter A, Abramovits W, Cõlon LE, et al,. Comparing clobetasol propionate 0·05% spray to calcipotriene 0·005% betamethasone dipropionate 0·064% ointment for the treatment of moderate to severe plaque psoriasis. J Drugs Dermatol 2009; 8: 52-7.
49. Thawornchaisit P, Harncharoen K,. A comparative study of tar and betamethasone valerate in chronic plaque psoriasis: a study in Thailand. J Med Assoc Thai 2007; 90: 1997-2002.
50. Beutner K, Chakrabarty A, Lemke S, Yu K,. An intra-individual randomized safety and efficacy comparison of clobetasol propionate 0·05% spray and its vehicle in the treatment of plaque psoriasis. J Drugs Dermatol 2006; 5: 357-60.
51. Bruce S, Epinette WW, Funicella T, et al,. Comparative study of calcipotriene (MC 903) ointment and fluocinonide ointment in the treatment of psoriasis. J Am Acad Dermatol 1994; 31: 755-9.
52. Jorizzo JL, Magee K, Stewart DM, et al,. Clobetasol propionate emollient 0.05 percent: hypothalamic-pituitary-adrenal-axis safety and four-week clinical efficacy results in plaque-type psoriasis. Cutis 1997; 60: 55-60.
53. Kragballe K, Noerrelund KL, Lui H, et al,. Efficacy of once-daily treatment regimens with calcipotriol/betamethasone dipropionate ointment and calcipotriol ointment in psoriasis vulgaris. Br J Dermatol 2004; 150: 1167-73.
54. Salmhofer W, Maier H, Soyer HP, et al,. Double-blind, placebo-controlled, randomized, right-left study comparing calcipotriol monotherapy with a combined treatment of calcipotriol and diflucortolone valerate in chronic plaque psoriasis. Acta Derm Venereol Suppl (Stockh) 2000; 211: 5-8.
55. van de Kerkhof PC, van der Valk PG, Swinkels OQ, et al,. A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: a randomized controlled trial of supervised treatment of psoriasis vulgaris in a day-care setting. Br J Dermatol 2006; 155: 800-7.
56. van de Kerkhof PC, Werfel T, Haustein UF, et al,. Tacalcitol ointment in the treatment of psoriasis vulgaris: a multicentre, placebo-controlled, double-blind study on efficacy and safety. Br J Dermatol 1996; 135: 758-65.
57. Katz HI, Prawer SE, Medansky RS, et al,. Intermittent corticosteroid maintenance treatment of psoriasis: a double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen. Dermatologica 1991; 183: 269-74.
58. Kragballe K, Austad J, Barnes L, et al,. A 52-week randomized safety study of a calcipotriol/betamethasone dipropionate two-compound product (Dovobet/Daivobet/Taclonex) in the treatment of psoriasis vulgaris. Br J Dermatol 2006; 154: 1155-60.
59. Kragballe K, Austad J, Barnes L, et al,. Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 2006; 213: 319-26.
60. Griffiths CE, Finlay AY, Fleming CJ, et al,. A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0·05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat 2006; 17: 90-5.
61. Buckley C, Hoffmann V, Shapiro J, et al,. Calcipotriol plus betamethasone dipropionate scalp formulation is effective and well tolerated in the treatment of scalp psoriasis: a phase II study. Dermatology 2008; 217: 107-13.
62. Franz TJ, Parsell DA, Halualani RM, et al,. Betamethasone valerate foam 0·12%: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38: 628-32.
63. Franz TJ, Parsell DA, Myers JA, Hannigan JF,. Clobetasol propionate foam 0·05%: a novel vehicle with enhanced delivery. Int J Dermatol 2000; 39: 535-8.
64. Green C, Ganpule M, Harris D, et al,. Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp. Br J Dermatol 1994; 130: 483-7.
65. Jarratt M, Breneman D, Gottlieb AB, et al,. Clobetasol propionate shampoo 0·05%: a new option to treat patients with moderate to severe scalp psoriasis. J Drugs Dermatol 2004; 3: 367-73.
66. Jemec GB, Ganslandt C, Ortonne JP, et al,. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. J Am Acad Dermatol 2008; 59: 455-63.
67. -1) in the treatment of scalp psoriasis. Br J Dermatol 1994; 131: 678-83.
68. Kragballe K, Hoffmann V, Ortonne JP, et al,. Efficacy and safety of calcipotriol plus betamethasone dipropionate scalp formulation compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized controlled trial. Br J Dermatol 2009; 161: 159-66.
69. McKinnon C, Klaber MR,. Calcipotriol (Dovonex) scalp solution in the treatment of scalp psoriasis: comparative efficacy with 1% coal tar/1% coconut oil/0·5% salicylic acid (Capasal) shampoo, and long-term experience. J Dermatolog Treat 2000; 11: 21-8.
70. Olsen EA, Cram DL, Ellis CN, et al,. A double-blind, vehicle-controlled study of clobetasol propionate 0·05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis. J Am Acad Dermatol 1991; 24: 443-7.
71. Reygagne P, Mrowietz U, Decroix J, et al,. Clobetasol propionate shampoo 0·05% and calcipotriol solution 0·005%: a randomized comparison of efficacy and safety in subjects with scalp psoriasis. J Dermatolog Treat 2005; 16: 31-6.
72. Sofen H, Hudson CP, Cook-Bolden FE, et al,. Clobetasol propionate 0·05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. J Drugs Dermatol 2011; 10: 885-92.
73. Tyring SK, Mendoza N, Appell M, et al,. A calcipotriene/betamethasone dipropionate two-compound scalp formulation in the treatment of scalp psoriasis in Hispanic/Latino and Black/African American patients: results of the randomized, 8-week, double-blind phase of a clinical trial. Int J Dermatol 2010; 49: 1328-33.
74. van de Kerkhof PC, Hoffmann V, Anstey A, et al,. A new scalp formulation of calcipotriol plus betamethasone dipropionate compared with each of its active ingredients in the same vehicle for the treatment of scalp psoriasis: a randomized, double-blind, controlled trial. Br J Dermatol 2009; 160: 170-6.
75. Poulin Y, Papp K, Bissonnette R, et al,. Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis. J Dermatolog Treat 2010; 21: 185-92.
76. Luger TA, Cambazard F, Larsen FG, et al,. A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis. Dermatology 2008; 217: 321-8.
77. Smith DR, Bottomley JM, Auland M, et al,. Heterogeneity in the treatment of moderately severe scalp psoriasis in Scotland-results of a survey of Scottish health professionals. Curr Med Res Opin 2011; 27: 239-49.
78. British Association of Dermatologists, Primary Care Dermatology Society. Recommendations for the Initial Management of Psoriasis. London: British Association of Dermatologists, 2010.